Holen Sie sich die Stockscreener-App
5.60
0.72%
0.04
Handel nachbörslich:
5.66
0.06
+1.07%
Savara Inc Aktie (SVRA) Neueste Nachrichten
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
SVRA Technical Analysis & Stock Price Forecast - Intellectia AI
Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review - simplywall.st
Guggenheim Keeps Their Buy Rating on Savara (SVRA) - The Globe and Mail
Citizens reiterates Savara stock rating on regulatory progress By Investing.com - Investing.com Canada
Citizens reiterates Savara stock rating on regulatory progress - Investing.com
EMA validates Savara’s MOLBREEVI application for autoimmune PAP By Investing.com - za.investing.com
Savara (SVRA) MAA Submission in Europe Receives Validation - GuruFocus
Jefferies reiterates Savara stock Buy rating on approval confidence By Investing.com - Investing.com India
Jefferies sees Savara stock approval odds at 90% for rare lung drug - Investing.com Canada
Jefferies reiterates Savara stock Buy rating on approval confidence - Investing.com UK
Jefferies sees Savara stock approval odds at 90% for rare lung drug By Investing.com - Investing.com South Africa
Savara : Corporate Presentation - marketscreener.com
Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). - Bitget
EMA validates Savara’s MOLBREEVI application for autoimmune PAP - Investing.com
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages - marketbeat.com
Savara grants inducement equity awards to new employee - MSN
Death Cross: Whats the fair value of Savara Inc stockTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
High Growth Tech Stocks To Watch In The US March 2026 - Sahm
Savara (SVRA) to Release Earnings on Tuesday - marketbeat.com
Savara’s MOLBREEVI BLA Receives FDA Priority Review - msn.com
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval - MyChesCo
Savara Inc devrait afficher une perte de 12 cents par actionEarnings AVANT-PAPIER - TradingView
Aug Big Picture: What is the Moat Score of Savara IncNew Guidance & Stock Market Timing Techniques - baoquankhu1.vn
Savara (SVRA) CFO exercises stock options and ends with 536,032 shares - Stock Titan
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative? - simplywall.st
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):